Tempest Therapeutics
TPST on Nasdaq. Market value $5m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 21 funds in all.
Largest holders overall
- Sabby Management$567,527Added
- Versant Venture Management$299,447
- Vanguard Capital Management$259,616
- Geode Capital Management$96,155
- Vanguard Fiduciary Trust$76,488
- BlackRock$43,365
- Squarepoint Ops$34,299New
- Northern Trust$22,351Added
- Citadel Advisors$22,000New
- UBS Group AG$6,255Added
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- Matthew AngelInsider or founder37.4%+1.5 ptsSince 24 March 2026
- SABBY MANAGEMENT, LLCPassive investorat least 9.9%(filed with 2 related holders)Since 31 December 2025
- Versant Ventures IV, LLCPassive investorSold down below 5%Since 11 August 2025
- Versant Vantage II, L.P.Passive investorSold down below 5%Since 30 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Matthew Angel Insider or founder | 37.4%+1.5 pts | 24 March 2026 | |
SABBY MANAGEMENT, LLC Passive investor | at least 9.9% (filed with 2 related holders) | 31 December 2025 | |
Versant Ventures IV, LLC Passive investor | Sold down below 5% | 11 August 2025 | |
Versant Vantage II, L.P. Passive investor | Sold down below 5% | 30 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $1m of shares on the open market.
- Angel MatthewCEO and President, DirectorBought
- Date
- 24 March 2026
- Shares
- 231,482
- Price
- $2.16
- Value
- $500,001
- Angel MatthewCEO and President, DirectorBought
- Date
- 24 March 2026
- Shares
- 231,482
- Price
- $2.16
- Value
- $500,001
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 24 March 2026 | Angel Matthew CEO and President, Director | Bought | 231,482 | $2.16 | $500,001 |
| 24 March 2026 | Angel Matthew CEO and President, Director | Bought | 231,482 | $2.16 | $500,001 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Tempest Therapeutics’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 13 Nov 2026 and 27 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these condensed consolidated financial statements.”
Show the full paragraph
The Company expects that its existing cash and cash equivalents will fund the Company’s projected operating expense requirements through less than 12 months from the date our condensed consolidated financial statements were available to be issued. Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these condensed consolidated financial statements. The accompanying condensed consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These condensed consolidated financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities; however, such adjustments may be necessary in the future when the Company is unable to continue as a going concern.
From the 10-Q filed 13 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
The company just told the SEC about a big change. The deep dive shows what it means for the price you pay.
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.